NCT06984341 - A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 1, 2033

Study Completion Date

November 1, 2033

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL

P-CD19CD20-ALLO1 Cells

P-CD19CD20-ALLO1 cells will be administered intravenously as per the schedule specified in the protocol.

DRUG

Cyclophosphamide

Cyclophosphamide will be administered intravenously.

DRUG

Fludarabine

Fludarabine will be administered intravenously.

DRUG

Rimiducid

Rimiducid will be used as a rescue therapy in the event of the occurrence of severe or life-threatening adverse events. It will be administered intravenously.